Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig E. Hunsaker Sells 13,878 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig E. Hunsaker sold 13,878 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total transaction of $171,532.08. Following the completion of the sale, the executive vice president now directly owns 1,450,018 shares of the company's stock, valued at $17,922,222.48. This trade represents a 0.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Alphatec Stock Up 2.3%

Alphatec stock traded up $0.29 on Friday, hitting $12.73. 1,224,032 shares of the stock traded hands, compared to its average volume of 2,041,237. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The business's fifty day simple moving average is $11.47 and its 200 day simple moving average is $10.74. The firm has a market cap of $1.86 billion, a P/E ratio of -9.95 and a beta of 1.10. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $13.14.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. During the same period in the prior year, the company posted ($0.34) earnings per share. The company's revenue was up 22.2% on a year-over-year basis. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of Alphatec

A number of institutional investors and hedge funds have recently modified their holdings of ATEC. Rhumbline Advisers lifted its holdings in shares of Alphatec by 6.9% during the first quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock valued at $1,508,000 after purchasing an additional 9,661 shares in the last quarter. Belpointe Asset Management LLC lifted its holdings in Alphatec by 23.3% in the first quarter. Belpointe Asset Management LLC now owns 18,500 shares of the medical technology company's stock valued at $188,000 after acquiring an additional 3,500 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Alphatec by 18.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company's stock worth $2,696,000 after purchasing an additional 41,264 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Alphatec in the 1st quarter worth $257,000. Finally, Parkman Healthcare Partners LLC raised its holdings in Alphatec by 95.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 446,106 shares of the medical technology company's stock worth $4,524,000 after purchasing an additional 217,772 shares during the period. Institutional investors own 66.35% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Piper Sandler restated an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Wall Street Zen raised Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Alphatec in a report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.